with a valuation inline with JAZZ , compare QCOR with
JAZZ, they are very similar in terms of all major numbers.
QCOR only has to grow 150 RX for NS and RA to increase
sales $20M Q to Q, 2103 Q1 earnings report in April is going
to be the NFLX moment in Jan, My Q1 sales estimate:
$160M base + $20M growth + $7 BioVectra = $187M,
earnings: 40% net X187 / 58 = $1.29/share are my bets.
I did a bottom up estimate and $1.29 is EXACTLY the number I have estimated (previously). Remember I have NAILED the last two quarters (a fraction of a cent off Q4) and 2 cents too low on Q3. I expect to go 3 for 3!!!
With Mikey's good news on insurance coverage, we are
really in for a big surprise in April, and expect Wallstreet
estimates to catch up to yours of 2013 $6+ by end of April,
I use JAZZ to quide for valuation of QCOR, so my $55 to $58
is fair price target. The sales growth is very simple to figure
out, for last 3 Qs, QCOR grew about $20M Q to Q.
With NS growing strong in Q4 and RA starting to take off,
average $20M Q to Q is eazy because 1 NS RX uses
8 vials for 6 month treatments and 1 RA uses 5 vials for
3 month treatments.